The DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Self-efficacy: Toward a unifying theory of behavioral change
Bandura, A. (1978) · Advances in Behaviour Research and Therapy · doi:10.1016/0146-6402(78)90002-4 · Cited by 10,586
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
Negative Self-Efficacy and Goal Effects Revisited
Bandura, A., & Locke, E. A. (2003) · Journal of Applied Psychology · doi:10.1037/0021-9010.88.1.87 · Cited by 2,813
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 1×
“One of the objectives of the present paper is to reinforce the point so well argued by others (McLellan et al., 2000) that drug and alcohol dependence are, in fact, chronic relapsing disorders which share numerous characteristics with other chronic relapsing medical conditions such as hypertension,…”
BackgroundNeurogenetic Adaptive Mechanisms in Alcoholism
Cloninger, C. R. (1987) · Science · doi:10.1126/science.2882604 · Cited by 2,234
Inheritance of Alcohol Abuse: Cross-Fostering Analysis of Adopted Men
Cloninger, C. R. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780330019001 · Cited by 1,873
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Cited by
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.004 · Cited by 720
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
The clinical significance of drug craving
Tiffany, S. T., & Wray, J. M. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06298.x · Cited by 556
A key role for corticotropin-releasing factor in alcohol dependence
Heilig, M., & Koob, G. F. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.006 · Cited by 503
Self-citationSommer, W. H., Rimondini, R., Hansson, A. C., Hipskind, P. A., Gehlert, D. R., Barr, C. S., & Heilig, M. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.010 · Cited by 309
Self-citationRichardson, H. N., Lee, S. Y., O’Dell, L. E., Koob, G. F., & Rivier, C. L. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06455.x · Cited by 294
A genetic determinant of the striatal dopamine response to alcohol in men
Ramchandani, V. A., Umhau, J., Pavon, F. J., Ruiz-Velasco, V, Margas, W., Sun, H., Damadzic, R., Eskay, R., Schoor, M., Thorsell, A., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.56 · Cited by 298
Self-citationUpdate on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264
Breese, G. R., Sinha, R., & Heilig, M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.09.007 · Cited by 261
Self-citationSchwandt, M. L., Cortes, C. R., Kwako, L. E., George, D. T., Momenan, R., Sinha, R., Grigoriadis, D. E., Pich, E. M., Leggio, L., & Heilig, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.61 · Cited by 159
Self-citationSemaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid Sköldheden, S., Zentveld, L., Vallöf, D., Tufvesson-Alm, M., & Jerlhag, E. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104642 · Cited by 158
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Comparing topiramate with naltrexone in the treatment of alcohol dependence
Baltieri, D. A., Daró, F. R., Ribeiro, P. L., & De Andrade, A. G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02355.x · Cited by 145
Targeting glutamate uptake to treat alcohol use disorders
Rao, P. S. S., Bell, R. L., Engleman, E. A., & Sari, Y. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00144 · Cited by 136
“In general, AUDs define a chronic, progressive, relapsing disorder that advances in stages from experimentation to dependence (Volkow and Li, 2005; Heilig and Egli, 2006; Koob and Le Moal, 2008; Koob, 2009; Spanagel, 2009; Jupp and Lawrence, 2010; Koob and Volkow, 2010).”
BackgroundNealey, K. A., Smith, A. W., Davis, S. M., Smith, D. G., & Walker, B. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.012 · Cited by 133
Cellular and behavioral interactions of gabapentin with alcohol dependence
Roberto, M., Gilpin, N. W., O'Dell, L. E., Cruz, M. T., Morse, A. C., Siggins, G. R., & Koob, G. F. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-08.2008 · Cited by 126
Cocaine craving and use during daily life
Preston, K. L., Vahabzadeh, M., Schmittner, J., Lin, J.-L., Gorelick, D. A., & Epstein, D. H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1655-8 · Cited by 123
“Craving has also been identified as a potential treatment target (Addolorato et al. 2005; Heilig and Egli 2006; Leyton et al. 2005), though in this context, as well, some authors have expressed skepticism (Kosten et al.”
ResultBlednov, Y. A., & Adron Harris, R. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008584 · Cited by 123
“As mentioned above, acamprosate is one of three drugs approved by the FDA for treatment of alcoholism (Heilig and Egli, 2006).”
BackgroundHeilig, M., Thorsell, A., Sommer, W. H., Hansson, A. C., Ramchandani, V. A., George, D. T., Hommer, D., & Barr, C. S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.018 · Cited by 117
Self-citationCippitelli, A., Damadzic, R., Singley, E., Thorsell, A., Ciccocioppo, R., Eskay, R. L., & Heilig, M. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.016 · Cited by 84
Self-citationPharmacological approaches to reducing craving in patients with alcohol use disorders
Haass-Koffler, C. L., Leggio, L., & Kenna, G. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0149-3 · Cited by 83
Kufahl, P. R., Martin-Fardon, R., & Weiss, F. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.174 · Cited by 72
“…reinforcing and dependence-inducing actions of ethanol and have identified these receptors as possible treatment targets for alcoholism (see, eg, Heilig and Egli, 2006). mGluR2/3 are located pre-, peri-, and post-synaptically (Benarroch, 2008), and negatively modulate glutamate transmission by…”
BackgroundGLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence
Jerlhag, E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.013 · Cited by 72
Alcohol and violence: neuropeptidergic modulation of monoamine systems
Miczek, K. A., DeBold, J. F., Hwa, L. S., Newman, E. L., & de Almeida, R. M. M. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12862 · Cited by 67
Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1
Jerlhag, E. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146562 · Cited by 53
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Augier, E., Dulman, R. S., Rauffenbart, C., Augier, G., Cross, A. J., & Heilig, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.107 · Cited by 44
Self-citationWhat the alcohol doctor ordered from the neuroscientist
Heilig, M., & Leggio, L. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.07.023 · Cited by 25
Self-citationAranäs, C., Blid Sköldheden, S., & Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1180512 · Cited by 20
“, 2009), and the limited efficacy of available treatments is thus a major concern (Heilig and Egli, 2006).”
Background(2014) · Työväentutkimus Vuosikirja · Cited by 1
Metadata
- Authors
- HEILIG, M., & EGLI, M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 111
- Issue
- 3
- Pages
- 855-876
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2171098630
- Cited by
- 377
- References
- 208
- FWCI
- 21.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.